Navigation Links
Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Date:5/27/2009

SAN DIEGO, May 27 /PRNewswire/ -- Verus Pharmaceuticals, Inc. ("Verus"), a specialty pharmaceutical company, announced today that it has filed a lawsuit against AstraZeneca AB ("AstraZeneca") and Tika Lakemedel AB ("Tika") in the Supreme Court of the State of New York, in which it is seeking $1.3 billion on claims of fraud, breach of contract, and conversion. Verus claims that AstraZeneca and its wholly owned subsidiary Tika disregarded their obligations under three agreements with Verus, entered into in 2007, pursuant to which the defendants were to pursue the research and development of Verus' assets, including budesonide, a steroid for the treatment of pediatric asthma in the United States. Verus further alleges that defendants' representations that induced Verus to enter into the agreements constituted fraud.

About Verus

Verus is dedicated to improving the lives of children and those who care for them. More information about Verus is available on the company's corporate website at www.veruspharm.com.

Verus(R) is a registered trademark of Verus Pharmaceuticals, Inc.

Forward-Looking Statements

Verus cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Verus that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Verus' business. All forward-looking statements are qualified in their entirety by this cautionary statement and Verus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company Contact:
    Blair C. Fensterstock, Esq.,
    Managing Director
    Fensterstock & Partners LLP
    BFensterstock@fensterstock.com
    212-785-4100 Office; 917-689-1137 Cell


'/>"/>
SOURCE Verus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Adolescent Growth Plate Injuries May Be Related to Overuse
2. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals: Risks of Overusing Antibiotics
3. Kids Overuse Sports Injuries Are on the Rise
4. Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment?
5. Urgent need for research into the best treatment for medication overuse headaches
6. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
7. Overuse of Opioids, Barbiturates Boosts Chronic Migraine Risk
8. ReachMD and VerusMed Broadcast Medical Conference Coverage on XM Satellite Radio
9. Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer
10. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
11. Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: